GLP1_NEW
Tern60 po 500mg qd
TERN60_PO_500MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.55 (0.07 to 30.97) | 0.44 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.43 (0.52 to 13.87) | 0.44 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.10 (2.82 to 22.50) | 0.21 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 15.20 (3.38 to 103) | 0.15 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.02 (0.51 to 10.71) | 0.47 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.70 (0.86 to 22.68) | 0.29 |